DRREDDY Dr. Reddy's Laboratories Q2 FY26 results (Jul–Sep 2025) and concall
TVS Motor delivered exceptional Q2 FY26 results, continuing its strong outperformance versus industry benchmarks. The company achieved record quarterly sales volumes while expanding margins through operational leverage and strategic positioning. Despite EV segment facing temporary magnet availability challenges, the company maintained growth momentum across all categories. New product launches including Apache RTX and upcoming Norton portfolio position the company well for premium segment expansion. Strong H1 performance sets positive foundation for remainder of FY26.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 5,015 | 5,563 | 7,810 | 4,619 |
| EBITDA | 1,192 | 1,443 | 3,837 | 480 |
| Net profit | 849 | 1,201 | 2,961 | 387 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
